AIM ImmunoTech (AIM) Current Leases (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Current Leases came in at $255000.0 in Q1 2026, up 8.97% YoY from $234000.0 in Q1 2025, and up 2.0% on a QoQ basis from $250000.0 in Q4 2025.
AIM ImmunoTech (AIM) Current Leases (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 14 years of Current Leases data on file, last reported at $255000.0 in Q1 2026.
- Quarterly Current Leases rose 8.97% year-over-year to $255000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255000.0 (up 8.97% YoY) and the FY2025 annual result came in at $250000.0, up 4.6% from the prior year.
- Current Leases grew to $255000.0 in Q1 2026, from $250000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $255000.0 in Q1 2026 to a low of $60000.0 in Q1 2022.
- A 5-year average of $207411.8 and a median of $232000.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases jumped 381.08% — and 2025, when it fell 2.5%.
- Tracing AIM's Current Leases over 5 years: stood at $178000.0 in 2022, then rose by 25.28% to $223000.0 in 2023, then climbed by 7.17% to $239000.0 in 2024, then climbed by 4.6% to $250000.0 in 2025, then grew by 2.0% to $255000.0 in 2026.
- The last three Current Leases figures came in at $255000.0 (Q1 2026), $250000.0 (Q4 2025), and $232000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 259,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 259,000.00 |
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 250,000.00 |
| Sep 30, 2025 | 232,000.00 |
| Jun 30, 2025 | 233,000.00 |
| Mar 31, 2025 | 234,000.00 |
| Dec 31, 2024 | 239,000.00 |
| Sep 30, 2024 | 232,000.00 |
| Jun 30, 2024 | 234,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 223,000.00 |
| Sep 30, 2023 | 207,000.00 |
| Jun 30, 2023 | 206,000.00 |
| Mar 31, 2023 | 178,000.00 |
| Dec 31, 2022 | 178,000.00 |
| Sep 30, 2022 | 171,000.00 |
| Jun 30, 2022 | 154,000.00 |
| Mar 31, 2022 | 60,000.00 |
| Dec 31, 2021 | 37,000.00 |
| Sep 30, 2021 | 36,000.00 |